Biocon settles Genentech dispute, sets 2027 Pebrilzo launch
Key highlights
- Biocon can launch Pebrilzo in the EU and UK in Q1 2027 under its Genentech settlement.
- Biocon's licensed US launch date for Pebrilzo is Q3 2028.
- Pebrilzo BLA #761501 was listed as USFDA-approved on November 12, 2026.
- The settlement resolved patent disputes in the US, Canada and other jurisdictions.
powered by IRIS

Biocon has settled patent disputes with Genentech over Pebrilzo, its biosimilar to Perjeta, securing licensed launches in the European Union and United Kingdom in the first quarter of 2027 and the United States in the third quarter of 2028. The settlement removes pending litigation in major markets but commercial terms remain confidential.
Know Biocon inside out
Results, valuation, peers and who's buying, in one view.
What did Biocon agree with Genentech?
Biocon has entered into a global settlement and licence agreement with Genentech covering Pebrilzo, a biosimilar of Perjeta. Perjeta is a cancer medicine used in HER2-positive breast cancer treatment. The agreement provides Biocon with defined entry dates in important international markets, subject to applicable regulatory approvals.
The settlement resolves pending patent disputes between the companies in the United States, Canada and other jurisdictions. Genentech had filed a patent-infringement case relating to Pebrilzo in a New Jersey court. The court dismissed that case at Genentech's request following the settlement.
The companies have not disclosed the financial or other commercial terms of the agreement. As a result, the available information does not quantify any settlement payment, royalty arrangement or expected revenue contribution for Biocon. The disclosed outcome is the removal of the legal disputes and the establishment of licensed launch timelines.
When can Biocon launch Pebrilzo in key markets?
Biocon can launch Pebrilzo in the European Union and the United Kingdom during the first quarter of 2027, while the licensed US launch is scheduled for the third quarter of 2028. Earlier reporting described the timing as early 2027 for the EU and UK and late 2028 for the US, consistent with the more specific quarterly timeline.
The agreement also contemplates launches in other markets between 2026 and 2028. Those launches remain dependent on regulatory approvals. A patent settlement does not replace the need for each relevant regulator to authorise the product before commercial distribution.
The source material also records Pebrilzo, with biologics licence application number 761501, as approved by the US Food and Drug Administration on November 12, 2026. The filing identifies pertuzumab as the active ingredient and solution for injection as the dosage form. The settlement's US launch date in the third quarter of 2028 remains later than the listed approval date because the patent licence defines when the product can be commercially introduced.
Got a follow-up? Ask IRIS
Why was the Genentech patent settlement important?
The Genentech settlement was important because patent litigation can delay a biosimilar's market entry even after regulatory progress. By setting licensed entry dates, the agreement gives Biocon a disclosed pathway for Pebrilzo in markets that include the US, the EU and the UK.
Biosimilars are biologic medicines designed to be highly similar to approved reference biologics. Their development and launch require regulatory review, manufacturing capabilities and, in many cases, the resolution of intellectual-property disputes. The Pebrilzo agreement addresses the litigation component for the jurisdictions identified by Biocon and Genentech.
The development comes as Biocon continues to build its biologics portfolio. The source material notes that Biocon Biologics received USFDA approval for denosumab biosimilars Bosaya and Aukelso, with provisional interchangeability status. It also reports a USFDA Establishment Inspection Report for a Bengaluru biologics drug-product unit, following an inspection during August.
These developments relate to different products and regulatory processes. Still, they show that legal settlements, regulatory clearances and manufacturing compliance are all relevant to a biosimilar company's ability to bring products to market.
How does the agreement affect Biocon and biosimilar investors?
The agreement gives Biocon specified commercial entry windows for Pebrilzo, but it does not provide a disclosed estimate of sales, margins, market share or the settlement's financial impact. Investors therefore have confirmed launch timing and litigation resolution, but not enough published information to calculate the product's contribution to earnings.
For operations, the settlement enables planning around regulatory submissions, supply arrangements and market preparation ahead of the stated launch dates. The US launch remains contingent on regulatory requirements, while the agreement addresses the patent-related route to commercial entry. The EU and UK launch window begins earlier, in the first quarter of 2027.
The wider biosimilar industry operates through a combination of scientific, regulatory and intellectual-property milestones. A product approval alone may not determine launch timing, as illustrated by Pebrilzo's listed USFDA approval and its later licensed US entry date. The agreement makes that timing explicit for this product.
No Biocon share-price movement was provided in connection with the Pebrilzo settlement. The source material separately reported a 2% rise in Biocon shares to Rs 361.25 after USFDA approval for Bosaya and Aukelso. That movement related to the denosumab biosimilars and should not be treated as a market reaction to the Genentech settlement.
Conclusion
Biocon's settlement with Genentech resolves pending patent disputes over Pebrilzo and provides scheduled launch points for its pertuzumab biosimilar. The company can target the EU and UK in the first quarter of 2027, followed by the US in the third quarter of 2028, subject to regulatory requirements and market-specific execution.
The next disclosed milestones are the planned regional launches, including other markets between 2026 and 2028. Investors will also need to watch for regulatory updates, launch confirmations and any later company disclosures on commercial terms, sales expectations or the financial contribution of Pebrilzo.


